- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00480714
A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers
A Study of the Immunogenicity of M. Bovis BCG (SSI Strain), Delivered Intradermally in Healthy Volunteers
Study Overview
Detailed Description
Volunteers for the study will be recruited through advertisements. Each volunteer will have received an information sheet concerning the study and will have agreed to participate in writing.
Volunteers will be given at least 48 hours between reading the information leaflet and agreeing to participate. Female volunteers will have a pregnancy test prior to enrollment. Volunteers will give signed consent for their GP's to be notified about their participation in the trial. The GP will be faxed a letter on the day of screening and asked to reply if they know of a reason why the volunteer should not take part. The signed consent form will also be faxed with the letter.
A week after the screening visit and after a negative Heaf test, subjects will receive a single intradermal injection of 106 cfu M. bovis BCG in 0.1ml just inferior to the insertion of the deltoid muscle. Blood tests will be taken at the screening visit and day of immunisation, 1 and 2 weeks, and 1, 2, 3 and 6 months after the immunisation. 75mls will be taken on the screening visit, and 60mls will be taken on all subsequent visits. Screening samples will be tested for full blood count, biochemical screen and immunological assays to determine vaccine immunogenicity. Peripheral blood mononuclear cells will be prepared for cellular immunological assays to be performed without or following cryopreservation. Other serological measures of immune response, i.e.
antibody titres, will be assayed on frozen plasma samples. All blood tests will be taken within 1-3 days of the due date as described in the schedule above.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oxfordshire
-
Oxford, Oxfordshire, United Kingdom, OX3 7LJ
- University of Oxford, CCVTM, Churchill Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult aged 18-65 years.
- Normal medical history and physical examination.
- Normal urine dipstick, blood count, liver enzymes, and creatinine.
Exclusion Criteria:
- Exposure to TB/BCG vaccination at any point. Previous residence in a TB endemic area.
- Clinically significant history of skin disorder (eczema, psoriasis, etc.), allergy, immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness, psychiatric disorder, drug or alcohol abuse.
- Oral or systemic steroid medication or the use of immunosuppressive agents.
- Positive HIV or core HBV antibody test.
- Positive Heaf test
- Positive ANA or serum anti-DNA antibody.
- Confirmed pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The induction of T-cell responses
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Helen I McShane, University of Oxford
Publications and helpful links
General Publications
- McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med. 2004 Nov;10(11):1240-4. doi: 10.1038/nm1128. Epub 2004 Oct 24. Erratum In: Nat Med. 2004 Dec;10(12):1397.
- Pathan AA, Sander CR, Fletcher HA, Poulton I, Alder NC, Beveridge NE, Whelan KT, Hill AV, McShane H. Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials. PLoS One. 2007 Oct 24;2(10):e1052. doi: 10.1371/journal.pone.0001052. Erratum In: PLoS One. 2011;6(2).doi:10.1371/annotation/71208a01-eb32-469c-96ab-8d5e3c497fce.
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on TB
-
University of OxfordCompleted
-
University of OxfordMedical Research CouncilCompleted
-
University of OxfordCompleted
-
University of BergenCompleted
-
Tuberculosis Research Centre, IndiaInternational Union Against Tuberculosis and Lung Diseases; Sarvodaya Charitable... and other collaboratorsActive, not recruitingPre-Extensively Drug-Resistant Pulmonary TB | Treatment Intolerant Multidrug-Resistant Pulmonary TB | Non-responsive Multidrug-Resistant Pulmonary TBIndia
-
Seoul National University HospitalTerminatedTBKorea, Republic of
-
National Institute of Allergy and Infectious Diseases...Completed
-
Far Eastern Memorial HospitalUnknownProtective Effect in TB-DIH | TB-DIH Means: Drug Induced Liver Function AbnormalitiesTaiwan
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Centre for the AIDS Programme of Research in South...Amsterdam Institute for Global Health and Development; Global Alliance for... and other collaboratorsRecruitingTuberculosis | Drug Resistant Tuberculosis | MDR-TB | XDR-TBNigeria, South Africa, Ethiopia
Clinical Trials on BCG (SSI Strain)
-
TASK Applied ScienceCompleted
-
Radboud University Medical CenterActive, not recruitingEpigenetics | Trained Immunity | BCG VaccineNetherlands
-
Bandim Health ProjectUniversity of Southern DenmarkRecruitingMorbidity;Newborn | Non-specific Effects of Vaccines | Death, Infant | Morbidity;Infant | Death; NeonatalGuinea-Bissau
-
Bandim Health ProjectOdense University Hospital; Odense Patient Data Explorative Network; Municipality...CompletedCovid19 | Immunosenescence | Vaccine Preventable Disease | Morbidity | Non-specific Effects of Vaccines | Heterologous ImmunityDenmark
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of OxfordCompleted
-
University of OxfordUniversity of Birmingham; AerasCompleted
-
Green Cross CorporationCompletedTuberculosis | BCG Vaccination ReactionKorea, Republic of
-
The University of Texas Health Science Center at...TerminatedBladder CancerUnited States
-
Bandim Health ProjectUniversity of Southern DenmarkCompleted